The reduction in price target by HC Wainwright & Co. could lead to a negative short-term sentiment among investors, as it suggests a lower valuation expectation for Allogene Therapeutics. However, the maintenance of a Buy rating indicates the analyst still sees long-term value in the company, which may mitigate some negative impact.